Overview

Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer

Status:
Completed
Trial end date:
2002-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using exemestane plus bicalutamide may fight prostate cancer by reducing the production of androgens. It is not yet known if exemestane is more effective with or without bicalutamide in treating prostate cancer. PURPOSE: Randomized phase II trial to study the effectiveness of exemestane with or without bicalutamide in treating patients who have stage IV prostate cancer that has been previously treated with hormone therapy or surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Swiss Group for Clinical Cancer Research
Treatments:
Bicalutamide
Exemestane